| Character | Association | Population | Sample size | Reference |
| Serum VD levels and RA | Inverse | Poland | 97 cases, 28 controls | [132] |
| Serum VD levels and RA | Inverse | Meta-analysis | 1,143 cases, 963 controls | [133] |
| Serum VD levels and RA | Inverse | South European | 120 cases, 65 controls | [134] |
| Serum VD levels and RA | Inverse | Croatia | 53 RA patients | [135] |
| Serum VD levels and RA | Inverse | Caucasian (Argentina) | 42 cases, 48 controls | [136] |
| Serum VD levels and RA | Inverse | India | 80 cases, 80 controls | [137] |
| Serum VD levels and RA, IL-17/IL-23, and bone loss | Inverse | Chinese | 130 cases, 80 controls | [138] |
| Serum VD levels and RA | Inverse | Egypt | 63 cases, 62 controls | [139] |
| Serum VD levels and RA | Inverse | Saudi Arabia | 55 cases, 40 controls | [140] |
| Serum VD levels and RA and musculoskeletal pain | Inverse | Greece | 44 cases, 44 controls | [141] |
| Serum VD levels and RA | Inverse | Meta-analysis | 3,489 RA patients | [142] |
| Serum VD levels and RA, anti-CCP antibody | Inverse | Chinese | 154 cases, 60 controls | [143] |
| Serum VD levels and RA & associated complexities | Inverse | 13 European countries | 625 cases, 276 controls | [144] |
| Serum VD levels and disease severity | Inverse | Iran | 91 cases, 31 controls | [146] |
| Serum VD levels and RA | Inverse | Japan | 4,793 RA patients | [150] |
| Serum VD levels and RA | Inverse | Italy | 1,191 cases, 1,019 controls | [152] |
| Serum VD levels and RA | Inverse | Italy | 1,168 RA patients | [153] |
| Serum VD levels and RA associated depression and anxiety | Inverse | Northwest China | 161 RA patients | [167] |
| Serum VD levels and neuropathic pain in RA patients | Inverse | Turkey | 93 RA patients | [168] |
| Serum VD levels and RA | Inverse | COMORA cohort (15 countries) | 1431 RA patients | [157] |
| Serum VD levels and ROS in RA patients | Inverse | India | 100 cases, 50 controls | [169] |
| Combination therapy of VD + denosumab and H-BMD | Positive | Japan | 22 monotherapy, 21 combination therapy | [159] |
| (i) Serum VD levels and RA (ii) Serum VD levels and disease activity | (i) Inverse (ii) No association | Turkey | 55 cases, 45 controls | [147] |
| (i) Serum VD levels and disease activity (ii) Serum VD levels and RA | (i) No association (ii) Inverse | Iran | 99 cases, 68 controls | [148] |
|
|